Cobra Biologics and Recopharma enter agreement


To use MaxXpress cell line development service from Cobra to supply Fc fusion protein

Cobra Biologics, a manufacturer of biologics and pharmaceuticals is to supply a human Fc fusion protein to Recopharma using its maxXpress service.

Cobra Biologics will apply its maxXpress service to deliver a programme of vector construction using Ubiquitous Chromatin Opening Elements (UCOE) technology, transfectant pool generation, and supply, purification and protein characterisation.

The company says the service will allow Recopharma to form a quick and reliable assessment on the specific expertise of Cobra’s cell line development and analytical scientist teams.

Recopharma has developed a technology that uses mucins, naturally occurring proteins produced by epithelial tissues with many potential applications. The FC fused mucins will provide a natural alternative to ocular lubricants and tear substitutes that are at present available and set to be used as a treatment and prophylactic that tackles viral conjunctivitis.

Peter Coleman CEO of Cobra Biologics said: ‘Cobra’s maxXpress service allows customers to make a fast assessment as to whether the UCOE technology and cell development team are the best combination to take their protein forward to clinical trials.’

Sign up for your free email newsletter

Jan Holgersson, CEO/CSO of Recopharma, added: ‘A cell pool providing good yields will be an important commercial milestone on our path towards clinical studies with our dry eye disease lead compound.’